Evaluation of Clinical Outcomes After Revascularization in Patients With Chronic Limb-Threatening Ischemia: Results From a Prospective National Cohort Study (RIVALUTANDO)

A prospective, multicenter, cohort study from Italy December 2016 to 2018. For 287 patients with chronic limb-threatening ischemia (CLTI) who underwent open, endovascular, or hybrid lower extremity revascularization, the 30-day major adverse cardiovascular and limb events (MALE) rates were 3% 2%, respectively. At 1 year, overall survival, amputation-free freedom MALE, primary patency rate was 89%, 87%, 63%, 71%, Smoking, renal failure, Rutherford class ≥5, below-the-knee arterial disease significant predictors of amputation after multivariate analysis. Iloprost infusion a protective factor against cilostazol restenosis. Medical treatment, including statins, cilostazol, iloprost, associated improved 1-year restenosis amputation.